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Disparities in Child and Adolescent Psychoactive Medication Prescription Practices by 
Ethnicity and Race 
 
Key Points 
 Compared to their non-Latino white counterparts, children and adolescents from racial-
ethnic minority groups in the U.S. are less likely to receive prescriptions for psychoactive 
medication 
 Racial-ethnic minority children and adolescents are also significantly less likely to receive 
mental health care 
 Controlling for access to mental health care and for geographic variation reduces but does 
not eliminate variations in psychoactive prescriptions by race and ethnicity 
 Controlling for mental health need and level of impairment does not eliminate variations in 
psychoactive prescriptions by race and ethnicity 
 Reducing disparities will require coordinated efforts to educate families and providers, 
promotion of evidence-based practices, steps to overcome geographic and language 
barriers, and additional research for understanding the underlying reasons for variations in 
prescription patterns 
 
Introduction 
Understanding and eliminating racial/ethnic disparities in access and quality of mental care has 
emerged as a national priority as highlighted in the 2001 Surgeon General‘s report and the 
President‘s New Freedom Commission on Mental Health (U.S. Department of Health and Human 
Services, 2001).  Despite similar prevalence rates of mental health disorders to whites (with the 
exception of Latino children who appear to have higher rates than whites) and the 
overrepresentation of minorities in public service sector systems, minority youth and white 
American children receive mental health treatment at differing rates (Cunningham and Freiman 
1996; Cuffe et al., 1995; Costello et al., 1997; Zito et. al. 1998; Flisher et al., 1997; Lahey et al., 
1996).  For example, using the National Medical Expenditure Panel Survey, Cunningham and 
Freiman (1996) found that African American children were less likely than white children to have 
made a mental health outpatient visit. The difference could not be attributed to underlying 
socioeconomic, family-related, or regional differences between the groups.  
Mental Health Services Use by Racial/Ethnic Minority Children and Adolescents 
Disparities in mental health services use by race and ethnicity may have implications for 
variations in prescription patterns for psychoactive medications in children and adolescents by 
race/ethnicity. Although the research on the use of mental health services by minority children 
and youth is scarce, available evidence indicates unmet needs for this population (Lahey et. al. 
1996).  The following are some key studies reported in the Surgeon General‘s Report on mental 
health and children in youth. One studied showed that irrespective of the source of treatment 
used, African American children and youth are less likely than whites to receive any mental health 
treatment including school-based services (Cuffe et al., 1995; Costello et al., 1997).  The 
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investigators found that Puerto Rican youth who met criteria for a psychiatric condition in Puerto 
Rico were significantly less likely to use mental health services compared to minorities from other 
geographic sites. Of those Puerto Rican youth with a diagnosable mental disorder, only 20 
percent reported using mental health-related services (Leaf et al., 1996).  This study was unique 
in that it obtained a measure of unmet need that was based both on a diagnosis and on a 
significant degree of impairment, where impairment was related to key symptoms of the diagnosis 
(Flisher et al., 1997). In other study of children‘s use of mental health care in two communities in 
Texas (Galveston and the lower Rio Grande Valley) (the researchers found that Hispanics 
reported significantly fewer life-time counseling visits than white youth (2 versus 4) (Pumariega et 
al., 1998). Overall, the studies support that minority children are less likely to use mental health 
services irrespective of need.   
Variations in Prescription Patterns for Psychoactive Medications in Children and 
Adolescent by Race/Ethnicity 
 
Objectives 
 
The literature review presented in this brief focuses on studies which examine racial-ethnic 
variation in psychoactive prescribing practices for children and adolescents which may suggest 
disparities in care. In our review and discussion of this literature we follow the definition of 
disparities used in the Institute of Medicine‘s Unequal Treatment report:  
 
Disparities in healthcare are differences in the quality of healthcare that are not due 
to access related factors or clinical needs, preferences, and appropriateness of 
interventions.  
 
While many troubled children across all racial/ethnic groups do not receive needed mental health 
services, children from racial-ethnic minority groups are even less likely to receive care and 
demonstrate lower rates of receiving psychoactive medication prescriptions. This report 
addresses two main questions:  
1) Do differences in psychoactive medication prescription rates represent racial/ethnic 
disparities as defined by the IOM report?  
2) Are factors which perpetuate these disparities clarified in the literature?   
Methods 
 
To identify the literature on disparities in child and adolescent psychoactive medication 
prescription practice by race and ethnicity, we searched published literature using standard 
sources (Ovid/Medline, PubMed), reviewed the Institute of Medicine Unequal Treatment Report 
and findings from the Annual National Healthcare Disparities Report/SAMHSA National Survey. 
The search terms included psychoactive drugs, ethnic groups, adolescent, and a combination of 
disparities and psychoactive drugs, psychoactive drugs and race/ethnicity, insurance and 
psychoactive drugs in children, youth and adolescents.   
The search resulted in approximately 100 articles. We reviewed abstracts for all articles since 
1994 and from these identified 13 based on quality and relevance for full review. The two primary 
methodologies used in this literature are to study large databases of prescription claims for data 
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on prescription patterns and to use responses to large surveys which may prescribe data on 
prescription use. These articles also led us to review two national reports:  the National 
Healthcare Disparities Report by the Agency for Healthcare Research and Quality, and the 
Institute of Medicine‘s Executive Summary, Unequal Treatment: Confronting Racial and Ethnic 
Disparities in Health Care. 
 
Results 
 
The primary studies that form the basis for this report are summarized and compared in Tables 1 
and 2. They represent studies conducted within the last 10 years using sound scientific methods 
for examining ethnic-racial disparities in psychoactive prescription patterns and associated factors 
which may contribute to the disparities.   
 
Table 1 is organized by the psychoactive class studied: stimulants, antidepressants, 
antipsychotics, and multiple classes. Primary limitations of each study are noted for each study. 
Table 2 is organized alphabetically and allows studies to be compared more easily. Any 
recommendations offered by the authors are included in this table. Full citations are provided in 
the References section. 
 
Variations in psychoactive prescriptions patterns by race/ethnicity: 
 Differential use across race/ethnicity groups has been identified using data from case 
studies Medicaid claims data, and nationally representative survey data.  Overall, the 
literature on prescription patterns suggests that white youth are more likely to be 
prescribed psychoactive medications as compared to racial-ethnic minorities. African 
American and Latino/Hispanic are the two ethnic/racial minority groups most often studied. 
Asians, Native Americans and other groups have been studied less due to their small 
numbers in the commonly used databases.  
 Large differences have also been found in psychoactive use across groups defined by 
insurance status.  Several studies indicated that antipsychotics are more likely to be 
prescribed to children with public insurance.  
 Disparities in both prescription pattern and use are consistently greatest for stimulant 
medications.  
Possible explanations – Disparities have been attributed to several factors including prescriber 
and family preferences or bias, private vs. public insurance, and the mental health care 
system itself.  More research is needed in understanding which factors mediate differences in 
prescription patterns across racial/ethnic groups. Some studies have made an attempt at 
approaching this question: 
 Unequal access 
o Racial-ethnic minority children are less likely to have a usual source of care and 
more likely to be uninsured.  However, in most studies which control for number of 
visits variations in prescription patterns still remain. 
o Studies which use Medicaid prescription databases (Zito, 2005; 1998) at least 
partially control for access to mental health care because all have Medicaid and 
other studies control for access in regression models (Hudson 2007). The only 
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study we found which controls for number of mental health visits (Olfson, 2006) 
found that racial/ethnic minority differences in antipsychotic prescriptions became 
nonsignificant controlling for mental health visits. However, the disparity between 
public vs. private insurance remained. Several studies indicated that antipsychotics 
are more likely to be prescribed to children with public insurance. As children on SSI 
because of a mental health disability and children in foster care are 
disproportionately more likely to receive public insurance, this finding has been 
attributed to greater severity of illness in this population. 
o Differences in utilization of mental health care – In studies conducted with minority 
community samples, distrust of mental health professional and of medications, 
religious practices, and social network support were identified as explanations for 
lower utilization of psychoactive medications.  The research also shows that 
racial/ethnic minorities are less likely to access services and once they enter 
services are less likely to be retained.  
o Geographical variation due to racial/ethnic population differences within states and 
across regions of the country account for some but not all of the disparity. 
Geographic location or place of residence may also be a critical factor in access to 
and quality of child mental health services. 
 Unequal treatment 
o Discriminatory treatment/prescribing practices: Racially biased diagnosis of adults 
with schizophrenia has been well documented, but similar studies have not been 
conducted with children.  Yet it is well known that race/ethnicity and culture affect 
symptom presentation and are likely to influence diagnosis and treatment by 
prescribers who are mostly white. 
o The well-designed study by Hudson et al (2007) found that the majority of 
racial/ethnic differences in children's stimulant use are explained by differences in 
responses to individual/family characteristics. In particular, black children in fair/poor 
mental health, with a child limitation (e.g., academic difficulty) or other impairment 
all have substantially lower probabilities of stimulant use than white children 
identified with the same mental health and behavioral issues. Hispanic children with 
a child limitation also have a lower probability of stimulant use than their white 
counterparts. The possible explanations suggested by the authors include 
discrimination in medical treatment and/or access to care, and cultural differences 
(racial/ethnic and/or community) in the diagnosis and treatment of behaviors 
associated with ADHD. In particular, culture may play a large role in determining 
how parents respond to the behavioral cues of their children, in their level of 
confidence in the medical system, and in their beliefs about the effectiveness or 
appropriateness of using medications to treat mental health and behavioral 
problems. 
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Table I: Summaries of Primary Studies Reviewed by Psychoactive Class 
 
a) Antidepressants 
Article Reference AHRQ, Annual National Healthcare Disparities Report 2007, 
Department of Health and Humans Services Agency (2008) 
Ages studied/sample 
number/ region/ data 
source 
12-17yo/National /Substance Abuse and Mental Health Services 
Administration (SAMHSA), National Survey on Drug Use and Health, 
2005 
Results/prescription 
variation/findings 
In 2005, in no group did even half of children 12-17 with major 
depressive episode receive treatment for depression in the past year. 
No statistically significant differences on the basis of race, ethnicity, or 
family income in the proportion of children ages 12-17 with major 
depressive episode who received treatment for depression in the past 
year. 
Any 
explanations/attribution 
of differences 
The prevalence of mental disorders for racial and ethnic minorities is 
similar to that of whites. However, research based evidence has 
shown minorities have less access to mental health care and are less 
likely to receive needed service. These differences may reflect, in 
part, socioeconomic status, variation in preferences and cultural 
attitudes toward mental health and mental health care. 
Limitations Data for Asians, Native Americans or Other Pacific Islander, American 
Indian or Alaska Native, and multiple races did not meet criteria for 
statistical reliability due to small sample sizes. 
b) Antipsychotics 
Article Reference Olfson, M., Blanco, C., Liu, L., Moreno, C., & Gonzalo, L., National 
Trends in the Outpatient Treatment of Children and Adolescents 
With Antipsychotic Drugs (2006) 
Ages studied/sample 
number/ region/ data 
source 
<20yo/National Ambulatory Medical Care Surveys (NAMCS) 1993 to 
2002  
Results/prescription 
variation/findings 
Analysis of national antipsychotic use by race and ethnicity found 
White adolescents more likely to be prescribed antipsychotics in 
office-based setting; they also had 3 times more mental health visits 
and general health care visits. When controlling for a number of visits 
the odds ratio for White youth compared to ethnic minority groups 
were no longer significant.  
Antipsychotic prescriptions were also greater for youth on Medicaid as 
compared to those w/ private insurance. Differences remained after 
adjusting for patient diagnosis and other background characteristics. 
Any 
explanations/attribution 
of differences 
Minority children and adolescents tend to be underserved in office-
based settings.  Illness severity may account for difference between 
public and private because insurance covers children with SSI due to 
mental health disability and children who are medically needy in foster 
care. 
Limitations Information is unavailable concerning dosages and duration of 
prescribed antipsychotic and other psychotropic medication; samples 
restricted to office based visit possibly underestimating outpatient 
antipsychotic treatment. 
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c) Stimulants 
Article Reference Hudson, J.L., Miller, G.E. & Kirby, J.B., Explaining Racial and 
Ethnic Differences in Children’s Use of Stimulant Medications 
(2007) 
Ages studied/sample 
number/ region/ data 
source 
5-17yo/ National /Medical Expenditure Panel Survey (MEPS) 2000-
2002 
Results/Prescription 
Variation/findings 
Focused on prescription for stimulants nationwide; differences in 
prescription rates were significant; white 5.1%, Black 2.8%, and 
Hispanic 2.1%. Although differences in access to care were also 
significant (Blacks and Hispanics were both less likely than whites to 
be insured). However, regression models showed these variables fail 
to account for any of the racial gap in stimulant use. 
Any explanations/ 
attribution of 
differences 
Although results suggest that most of the racial/ethnic gap in stimulant 
use is due to differences in the effects of individual /family 
characteristics on stimulant use, the source of these differences 
remains unclear. Possible explanations include discrimination in 
medical treatment and /or access to care and cultural differences 
(racial/ethnic and/or community) in the diagnosis and treatment of 
behaviors associated with ADHD. 
Limitations MEPS does not have clinical information on the prevalence of ADHD.  
 
 
Article Reference Stevens, J., Harman, J.S., & Kelleher, K.J., Race/Ethnicity and 
Insurance Status as Factors Associated with ADHD Treatment 
Patterns (2005) 
Ages studied/sample 
number/ region/data 
source 
3-18yo/(N=27802) /National survey; regional differences found/1997-
2000 Medical Expenditure Panel Surveys (MEPS) 
Results/prescription 
variation/findings 
Children w/o insurance had lower level of care in all stages of relative 
to children w/o insurance.  White Americans were more likely to be 
diagnosed with ADHD compared to African American and Hispanic –
American Youth. 
Children with Medicaid were more likely to be diagnosed with ADHD 
than were children without insurance. Significant group differences for 
age, ethnicity and type of insurance (p<0.05) but not region. 
Prescription Variations include: (1) Children with ADHD 7-12 and 13-
18 yrs. more likely to receive at least one stimulant prescription relative 
to those 3-6 yrs., (2) White children with ADHD more likely to receive 
at least one stimulant prescription compared to African-American 
children with ADHD but not compared to Hispanic-American children, 
(3). Children with ADHD with private insurance more likely to receive 
at least one stimulant compared to children with ADHD having public 
insurance or no insurance. 
Any explanations/ 
attributions of 
differences 
Hispanic-American and African –American children were less likely to 
be diagnosed with ADHD by parent report than white American 
children; African American youths with ADHD were less likely to initiate 
stimulant medication relative to White American children. Not 
surprisingly, 7-12 years olds were more likely to be diagnosed with 
ADHD compared with ages 13-18 who in turn were more likely to be 
diagnosed compared to children 3-6 yrs.   
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Uninsured children had a lower likelihood of ever receiving a stimulant 
prescription. Furthermore, compared to children with coverage, 
medicated children without insurance had fewer stimulant 
prescriptions, physician visits for ADHD, and fewer psychotherapy 
visits for both ADHD and comorbid conditions. 
Limitations None noted. 
d) Multiple classes 
Article Reference Zito, J.M., Safer, D.J., dosReis, S., & Riddle, M.A., Racial   
Disparity in Psychotropic Medications Prescribed for Youths With 
Medicaid Insurance in Maryland (1998) 
Ages studied/sample 
number/ region/ data 
source 
5-14yo/(N=99,217)/Maryland Medicaid prescription drug claims 
analyzed 
Results/prescription 
variation/findings 
African Americans were less than half as likely to receive psychotropic 
prescriptions as whites, and about 2/3 as likely to receive other non-
psychotropic medications. The greatest differences were found for 
stimulants with an OR of (1:2.5). 
Any explanations 
/attribution of 
differences 
The racial disparity of use was not altered by partial (noncontinuous 
enrollment) eligibility status; and, although controlling for geographic 
variation reduced the racial disparity, a twofold racial difference 
remained. 
Limitations Does not control for mental health service use/number of visits; based 
on single state Medicaid population; Because African American 
income was four times as likely than Caucasians to have more than 
half their income come from public assistance; African Americans may 
not be utilizing mental health services relative to Caucasians. 
 
 
Article Reference Zito, J.M., Safer, D.J., Zuckerman, I.H., Gardner, J.F., & Soeken, 
K., Effect of Medicaid Eligibility Category on Racial Disparities in 
the Use of Psychotropic Medications Among Youths (2005) 
Ages studied/sample 
number/ region/ data 
source 
2-19 yo/(N=217,900)/Maryland Medicaid prescription data  
Results/prescription 
variation/findings 
Follow up to same group‘s 1998 study examined differences in 
psychotropic medication prevalence in different eligibility categories 
within Medicaid. Categories reflect either income or special needs 
(youth on SSI for mental illness and youth in foster care who tend to 
have more severe mental illness). Ages studied; 2-19 years for the 
year 2000. There were not enough Hispanic youth (N=396) to 
compare separately; they were included in ‗other‘ category with Asian 
(N=110), Native American (N=37), Pacific Islander or Alaskan (N=1). 
Overall disparity was the same as in 1998 study. White youth as 
compared to African Americans were twice as likely to receive 
psychotropic medications and 3.75 times as likely as compared to the 
‗Other‘ minority group. Among psychotropic classes the disparity was 
greatest for antidepressants. 
Any 
explanations/attribution 
of differences 
These more detailed analyses are pertinent now that we have 
established that eligibility categories are crucial to an understanding of 
the racial disparity in psychotropic prevalence patterns.  
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Limitations Use of prescription claims precludes examination of other variables of 
interest such as diagnosis, treatment provider, and mental health 
service use (number of visits); single state Medicaid data. 
 
 
 
Article Reference dosReis, S., Zito, J.M., Safer, D.J., Gardner, J.F., Puccia, K.B., & 
Owens, P.L., Multiple Psychotropic Medication Use for Youths: A 
Two-State Comparison (2005) 
Ages studied/ sample 
number/ region/ data 
source 
<20yo/Maryland Medicaid & State Children‘s Health Insurance 
Programs (SCHIP) 
Results/prescription 
variation/findings 
Data from computerized administrative claims representing medical 
visits to health-care providers and medications dispensed from 
outpatient community pharmacies in 1999. 
Overall prevalence of multiple psychotropic medication use was about 
2-3%, of which nearly half was for 5-12 months. Prevalence was 
higher for males, whites, 10-14 year olds, disabled and severe mental 
illness. 
Any 
explanations/attribution 
of differences 
A considerable proportion of multiple uses involve antidepressant 
medications, and approximately 60% of antidepressant use was an 
SSRI. 
Limitations Differences in the definition of multiple psychotropic treatment limit 
comparisons to other studies; two state comparison of states in the 
mid-Atlantic regions. 
 
 
Article Reference Leslie, L.K. et al., Racial/Ethnic Differences in the Use of 
Psychotropic Medication in High-Risk Children and Adolescents 
(2003) 
Ages studied / sample 
number/ region/data 
source 
 6-17yo/(N = 1,715) sample of youths ages /San Diego County, 
CA./Patterns of Youth Mental Health Care in Public Service Systems 
(POC) 
Results/prescription 
variation/findings 
Race ethnicity distribution: whites (48.6%), African American (22.7 
%), Latino (19.4%) and Other (13.3%). A higher proportion of African 
Americans had public insurance.   
Overall results: Racial/ethnic differences in use of psychotropic 
medication occur in children served in public service sectors and 
need to be considered in clinical diagnosis and treatment. 
Despite high diagnosis rates, overall rates of psychotropic medication 
use in the past year was low (27.9%), with rates of lifetime use across 
the sample at 40.8%. For children who met DSM-IV criteria for mood 
and/or anxiety disorder or ADHD less than half (47.9%) had received 
mediation in the past year, 61.4% reported lifetime medication use. 
Females were less likely to report past year or lifetime psychotropic 
medication use. 
African American and Latino children were 0.59 and 0.46 times as 
likely to report past year medication use compared to whites: Latino 
and Other children were 0.41 and 0.55 times as likely to report 
lifetime medication use compared to whites. 
Any explanations Racial Disparities explanations in minorities include differences in the 
  
10 
/attributions of 
differences  
prevalence of psychiatric conditions; however, studies have shown 
some prevalence rates comparable and some higher. Unequal 
access to care includes fewer psychiatrist‘s practice in economically 
disadvantage neighborhoods and poor access to physicians. Unequal 
quality of care in comparison to whites includes uneven and /or poor 
quality side effect management and lack of psychoeduational 
information and provider bias to racial/ethnic backgrounds. Cultural 
factors may affect acceptance, poorer compliance rates and 
communication (language) barriers and side effects. 
Limitations Study could not address access, quality, cultural and genetic factors 
which may have affected treatments offered to children/families. 
Difficult to gauge the degree to which accessibility and 
appropriateness of services may have played a role in lower 
medication use. Racial/ethnic category included no heterogeneity 
within each group. Sample represents high-risk children in a single 
service system area. Missing Data: 134 missing medication data; 372 
missing DISC-IV data. Of the 372, 200 were Spanish speaking and 
had no translator at interview. 
 
 
Article Reference Raghavan, R. et al., Psychotropic Medication Use in a National 
Probability Sample of Children in the Child Welfare System 
(2005) 
Ages studied/sample 
number/region/data 
source) 
8yo mean age/48% (n=1479) were boys, 47% Caucasian, 28% 
African-American, and 18% Latino/Latina. (N=3114) children and 
adolescents/The National Survey of Child and Adolescent Well-Being  
Results/prescription 
variation/findings 
62% were Medicaid recipients; 87% were living at home; 14% saw a 
mental health provider only and 5% saw both a specialty and 3% saw 
a nonspecialty provider for a mental health problem.13.5% of children 
(threefold increase) were taking psychotropic medications at 
NSCAW‘s 12 month follow up. Mean age on medication was 10 
years; Mean age not on medication was 8 yrs.  
The proportion of children aged between12 and 16 years; medication 
use was 7 times greater than among children aged between 2 to 5 
years. 
Male gender, Caucasian race/ethnicity with a history of physical 
abuse, public insurance status, sub score above 60 on the CBCL 
were significantly associated with medication use. African-American 
and Latino race/ethnicity with a history of neglect and being uninsured 
were negatively associated with medication use. 
Any explanations/ 
attributions of 
differences 
5%-6% of psychotropic medication statewide uses among Medicaid 
children; among commercially insured children even lower 4%.  
Limitations Partly owing to small sample size, study does not permit us to identify 
many associations between type of provider visit, use of psychotropic 
medications, provider history based on parent and caregiver report, 
and no information on type, dosage and duration of medications taken 
by child. 
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Article Reference Richardson, L.P., DiGiuseppe, D., Garrison, M., & Christakis, 
D.A., Depression in Medicaid-Covered Youth (2008) 
Ages studied/sample 
number/ region/ data 
source 
(N=192,441) youth 5-18 years/ Washington State Medicaid claims 
data from July 1, 1997 to December 31, 1998 
Results/prescription 
variation/findings 
Compared with white youth, Hispanic, Asian/Pacific Islander and 
black youth were less likely to have a depression diagnosis. Following 
a new diagnosis, Native American (OR; 0.29) and Hispanics (OR; 
0.42) youth were less likely than white youth to receive an 
antidepressant or a mental health specialty visit (within 6 months 
following new episode of depression). 
Any explanations/ 
attribution of 
differences 
Physician identification of depressive disorders may differ by race and 
ethnicity. Mental Health disorders may be particularly prone to 
diagnostic bias because patterns of depressive symptoms and the 
stigma associated with mental health disorders are culturally based 
and cultural experiences may differ by race and ethnicity. Lack of trust 
in a physician; differences in depressive diagnosis may be due to 
racial and ethnic accessing care for mental health treatment 
preferences; continuity of regular medical care. 
Limitations One state Medicaid sample; claims may not represent all medical 
care youth receive; few black and Asian youth were diagnosed with 
depression resulting in small size for analysis. 
 
 
Article Reference Rushton, J.L. & Whitmire, T., Pediatric Stimulant and Selective 
Serotonin Reuptake Inhibitor Prescription Trends (2003) 
Ages studied/sample 
number/region/data 
source 
Population range from 342,333 in 1992 to 581,088 in 1998 of children 
ages 1-19 years/ State of North Carolina/Medicaid Database  
Results/ prescription 
variations /findings  
 
1992-1998 included all prescription claims (included age, sex, racial 
group county etc.) SSRIs & stimulants were studied. 
Overall stimulant prescription prevalence per number of  
pre-school age (1-5) and school age (6-14) doubled and SSRI 
prevalence rate increased even more during the 7 year period of the 
study. 
Racial demographics: 1992, 56.4 % of children prescribed stimulants 
and 75.9 % prescribed SSRI‘s were white. Racial difference narrowed 
between1992-1998. However, in 1998 50.6% stimulants and SSRI‘s 
65.9% were given to white children even though 48.3% of the 
Medicaid children were black, 39.7% white and 12% other racial 
groups.   
In 1998, stimulant prescriptions differed for white school aged males 
(18.3%) vs black females (3.4%) and SSRI‘s for white school aged 
males (2.8%) vs black females (0.6%). 
Asian, Hispanic, American Indian and other racial groups were less 
likely to receive stimulants and SSRI‘s. Sex differences also reported 
a male predominance of AD/HD. In 1998 male/female ratio was 3.2:1 
a decrease from 4.2:1 in 1992. SSRI‘s more predominant in females; 
in 1992 female /male ratio (1.8:1), but in1998 female/male was equal 
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(1:1). 
Any explanations/ 
attributions for 
differences  
 
  
Increased recognition and treatment of previously unrecognized 
mental disorders, improved access to psychiatric care, increased 
education about medications their harmful effects and negative 
association with expansion of prescription utilization. Differences were 
found in stimulant and increased SSRI prevalence for whites and 
other racial groups. But caution differences could be in miss 
classification, cultural beliefs of MI, access to care, different 
acceptance of psychotropics.  
Limitations Maryland Medicaid patients only. More attention to Hispanic Medicaid 
population needed across the U.S. population. Limited Hispanic data 
for analysis in this Medicaid state data. 
 
 
Article Reference Cuffe, S.P., Waller, J.L., Cuccaro, M.L., Pumariega, A.J., & 
Garrison, C.Z., Race and Gender Differences in the Treatment of 
Psychiatric Disorders in Young Adolescents (1995) 
Ages studied/sample 
number/ region/ data 
source 
7th, 8th & 9th grade adolescents/(N=478)/Washington State Medicaid 
claims data 
Results/prescription 
variation/findings 
Twenty-two percent of the sample had contact with professionals 
during the prior year, including 58% of adolescents with a psychiatric 
diagnosis. Trends for undertreatment of females and African-
Americans were evident in univariable and multivariable models. The 
OR (0.34) for African-American females was significant in the 
multivariable model. African Americans were significantly more likely to 
receive only one or two treatments contacts. 
Any explanations/ 
attribution of 
differences 
Referral bias; low cultural competence of mental health professionals, 
and cultural differences in the expression and tolerance of symptoms 
and help-seeking behaviors. 
Limitations Inferences from the results of this study are limited by the 
shortcomings of the diagnostic instrument and collection of relevant 
data. 
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Table 2: Comparison of Studies on Disparities in Children and Adolescent Psychoactive Medications 
First Author 
(year) 
Data Source/sample Primary findings on 
Race/ethnicity/other disparity 
Recommendations for addressing 
any disparities or identifying reasons 
AHRQ 
(2008) 
National Healthcare 
Disparities Report 2007 
U.S. Department of 
Health and Human 
Services/ SAMHSA 
National Survey 
SAMHSA National survey on drug use 
and health found that for 2005, in no 
group did even half of children 12-17 
years of age w/major depressive 
episode received treatment, but no 
significant racial/ethnic/income disparity 
in receipt of treatment. 
Prevalence of mental disorders for racial 
and ethnic minorities in US is similar for 
Whites…research based evidence has 
shown minorities have less access to 
mental health care & are less likely to 
receive needed services. Differences 
may reflect socioeconomic status, 
variation in preferences and cultural 
attitudes toward mental health and 
mental health care. 
Cuffe, S.P. 
(1995) 
(N=478) Seventh, eighth 
and ninth grade students/ 
Southeastern U.S. school 
district. 
Trends for undertreatment of females 
and African Americans were evident in 
univariable and multivariable models. 
The OR (0.34) for African American 
females was significant in multivariable 
model. African American were more 
likely to receive only one or two 
treatment contacts. 
Data suggest race and gender 
differences in treatment of adolescent 
psychiatric disorders. Possible referral 
bias, low cultural competence of mental 
health professionals, and cultural 
differences in the expression and 
tolerance of symptoms and help-seeking 
behaviors. 
dosReis, S.  
(2005) 
Age < 20 years, 
Administrative data 
examined multiple 
psychotropic use …a two 
mid-Atlantic state 
comparison of youth/1999 
Medicaid and SCHIP. 
Overall prevalence of multiple 
psychotropic medication use was about 
2-3%. Prevalence higher for males, 
whites, 10-14 year olds, disabled, and 
with severe mental illness. 
Many findings consistent with other 
studies regarding multiple psychotropic 
drug use; further investigations of the 
effectiveness and outcomes of 
combined pharmacotherapy can target 
this population. 
Hudson, J.L. 
(2006) 
(N=19,115) ages 5-17 
years/Medical 
Expenditure Panel Survey 
(MEPS)  
Focused on prescriptions for stimulants 
nationwide. Significant disparities; 
Whites 5.1%, Blacks 2.8%, Hispanic 
2.1%. 
Differences in access to care were 
significant (Blacks & Hispanics less 
likely than Whites to have a usual 
source of care & Hispanics were also 
about 3 times as likely as Whites to be 
uninsured). However, variables fail to 
account for racial gap in stimulant use. 
Leslie, L.K. 
(2003) 
(N = 1,715) sample of 
youth ages 6 - 17 yrs/ 
Patterns of Youth Mental 
Health Care in Public 
Service Systems (POC) 
 
Rates of psychotropic medication use 
of those given a diagnosis was low 
(27.9%), with rates of lifetime use at 
40.8%. Children with mood and/or 
anxiety disorder or ADHD; less than 
half (47.9%) on medication in past 
year; 61.4% lifetime. Minority groups 
40-60% less likely than Whites to report 
past year medication use. 
 
Studies have shown some prevalence 
rates comparable and some higher and 
unequal access to care. Fewer 
psychiatrists practice in economically 
disadvantage areas; poor access to 
physicians; unequal quality of care; 
uneven and /or poor quality side effect 
management; lacking 
psychoeducational information;  provider 
bias to racial/ ethnic  backgrounds etc. 
Olfson, M. 
(2006) 
Ages <20 years/National 
Ambulatory Medical Care 
Survey (NEMCS) 
Analysis by race/ethnicity found White 
adolescents, more likely to be 
prescribed antipsychotics, but also had 
3 times more mental & general health 
visits; when controlling for # of visits, 
the Odds Ratio for White youth 
compared to ethnic minority groups 
was no longer significant. Also, 
antipsychotics Rx' s greater in kids on 
Medicaid vs. private insurance. 
 
The lower population rate of 
antipsychotic treatment visits by children 
and adolescents of minority racial or 
ethnic ancestry appears to be more 
closely tied to a nonspecific tendency for 
these children  and adolescents to be 
underserved in office-based settings 
rather than tied to racial/ethnic 
differences in prescribing practices of 
office-based physicians. 
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First Author 
(year) 
Data Source/sample Primary findings on 
Race/ethnicity/other disparity 
Recommendations for addressing 
any disparities or identifying reasons 
Raghavan, 
R. (2005) 
 (N=1479) 48% boys, 47% 
Caucasian, 28% African-
American, and 18% 
Latino/a. (N=3114); 62% 
Medicaid; 87% at home; 
14% saw a MH provider; 
5% saw both specialty & 
3% nonspecialty for MH 
/The National Survey of 
Child & Adolescent Well-
Being. 
13.5% of children (threefold increase) 
were taking psychotropic medications 
at NSCAW‘s 12-month follow up. The 
proportion of mediation use among 
children 12-16 yrs was seven times 
greater than among children 2–5 yrs. 
Caucasian males were significantly 
associated with medication use. 
African-American & Latinos were 
negatively associated with medication 
use. 
5%-6% prevalence rates of 
psychotropic medication in statewide 
Medicaid children and among 
commercially insured children 
prevalence was even lower at 4%. 
 This sample is a point prevalence 
estimate at follow up only. 
 
 
 
Richardson, 
L.P. 
(2003) 
(N=192,441) youth aged 5-
18 years/Washington State 
Medicaid claims data 
Compared with White youth, 
Hispanics, Black and Asian/Pacific 
Islander youth were less likely to have 
a medical claim w/ depression 
diagnosis. Following a new diagnosis, 
Native American and Hispanic youth 
were less likely than White youth to 
have received an antidepressant or a 
mental health specialty visit. 
Physician identification of depressive 
disorders may differ by race/ethnicity 
(diagnosis bias); stigma is culturally 
based and cultural experiences may 
differ by race/ethnicity; Lack of trust in 
physicians limits mental health 
discussions. 
Rushton, 
J.L.     
(2001) 
(N=342,333) in 1992 to 
581,088 in 1998 of children 
ages 1-19 years/ State of 
North Carolina/Medicaid 
Database 
65.9% of prescriptions for stimulants 
and SRI‘s were to white children even 
though 48.3% of the Medicaid children 
were black, 39.7 % white and 12% 
other racial groups. Asian, Hispanic, 
American Indian and other racial 
groups less likely to receive stimulants 
& SSRI‘s. 
More research needed to address how 
psychotropic prescription practices 
affect utilization of other medical 
services, and differences by age, sex 
and race; immediate attention needed 
to address underprescribing to Hispanic 
youth across nationwide Medicaid 
population. 
Stevens, J.  
(2005) 
(N=27,802) observations of 
children 3-18 years/1997-
2000 Medical Expenditure 
Panel Surveys (MEPS) 
Children w/o insurance had lower level 
of care in all stages compared to 
those with insurance. White 
Americans more likely to be 
diagnosed with ADHD compared to 
African American & Hispanic –
American Youth. White children with 
ADHD more likely to receive at least 
one stimulant Rx compared to African-
American children w/ ADHD but not to 
Hispanic-Americans. 
Hispanic-American and African –
American children were less likely to be 
diagnosed with ADHD by parent report 
than white American children; African- 
American youths with ADHD were less 
likely to initiate stimulant medication 
relative to White American Children. 
Uninsured children had a lower 
likelihood of ever receiving a stimulant. 
Zito, J.M.  
(1998) 
 
(N=99,217) African-
American and Caucasian 
aged youth 5-14 years 
/Maryland Medicaid 
prescription drug claims 
analyzed 
African-Americans were less than half 
as likely to receive psychotropic 
prescriptions than whites and about 
2/3 as likely to receive 
nonpsychotropic prescriptions. 
Greatest ratio difference for stimulants 
was 1:2.5. 
Single state Medicaid population; Does 
not control for mental health service 
use/number of visits; Because African 
American income was four times as 
likely than Caucasians to have more 
than half their income come from public 
assistance; African Americans may not 
be utilizing mental health services 
relative to Caucasians. 
Zito, J.M.  
(2005) 
(N =217,900) youths aged 
2 to 19 years/Maryland 
Medicaid follow up study to 
‘98 examine prevalence of 
psychotropic medications in 
different eligibility 
categories 
Overall disparity was about the same 
as ‘98 study. White youth were 2.17 
times more likely to receive a 
psychotropic medication compared to 
African American youth, and 3.75 
times as likely compared to the 
―Other‖ minority group. Disparity was 
greater  
by income; Whites 3.2-3.8 times more 
likely to get psychotropic medications. 
Eligibility category should be taken into 
account when ascertaining the roles of 
access, undertreatment and culture in 
disparities. Not enough Hispanic youth 
to compare separately; they are 
included in the ―other‖ category with 
Asian, Native  
American, Pacific Islander or Alaskan. 
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Recommendations 
 
Available evidence shows that white children are more likely to be prescribed psychoactive 
medication compared to racial-ethnic children but are also more likely to report higher rates of 
mental health and general health visits compared to racial-ethnic children. The most common 
factors for which researchers have adjusted for in models have been access and services use.  
These factors have at least partially explained potential disparities for minority populations but 
other factors such as insurance status and geography have been identified in the literature. 
Specific psychoactive medications including stimulants and antidepressants have been well 
studied and suggest significant differences in prescription patterns. Other factors have been 
identified as influencing differences in prescription patterns: fewer psychiatrists practicing in 
economically disadvantage areas; poor access to physicians; unequal quality of care; uneven 
and /or poor quality side effect management; lack of psycho-educational information for certain 
communities; and provider bias to racial/ ethnic backgrounds. 
 
Parents, advocates, and protective service workers have expressed concern that minority 
children might be over-medicated and not provided with non-pharmacological services, relative to 
―white‖ children and youth. This observation is similar to the observation of disparate rates of 
coercive interventions (seclusion and restraint) among minority youth; the over-representation of 
minority youth in youth corrections (as opposed to mental health) settings, and the differential 
referral of minority youths seen in emergency wards. Differential access, limited resources, and 
provider bias are cited as possible causes.  However, the results from this literature review 
suggest that minority youth have lower rates of being prescribed psychoactive medications 
overall although antipsychotics may be more likely to be prescribed to youth with public 
insurance. More research is needed in the field of disparities research which examines the 
prescribing of medications concurrent with other mental health services including psychosocial 
treatments. Multi-modal treatments have been cited in the literature as efficacious and in many 
instances recommended as standard of care in the field of child psychiatry for such conditions as 
major depression (TADS study) and to a lesser degree ADHD (MTA study, NIH). As the field 
advances in that regard there is also a need to examine equitable access to quality care across 
race/ethnicity.  The use of psychoactive medication treatment of children is not an unqualified 
good especially if we are limited in our examination of the quality of services provided. However, 
variations in prescribing patterns by race-ethnicity are marked and warrant further study. 
 
Policy and Practice Implications 
 
Common recommendations which have been suggested in the literature for addressing mental 
health disparities (including those related to psychoactive medications) have included the 
following and are compatible with the mission of DMH:  
 
 Increase awareness of disparities among providers and families and throughout DMH 
 Consistency and equity of care should be promoted through the use of evidence-based 
guidelines for providers 
 Increase the numbers of minority providers 
 Increase availability of interpreters to overcome language barriers 
 Provide education programs for consumers to improve knowledge of mental illness and its 
treatment and their ability to participate in decision-making 
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 Collect and monitor data on patients‘ access and utilization of health care services by race, 
ethnicity, and primary language 
 Cultural competence trainings for providers and DMH workers with specific focus on 
disparities in psychoactive prescription and use among children. 
 
Recommendations for research 
Assessing the quality of treatment received and the appropriate prescribing practice of 
psychoactive medications to children and youth of different racial/ethnic backgrounds is beyond 
the scope of this report. However, recent legislation passed in the Commonwealth of 
Massachusetts which prioritizes child mental health screening and treatment may pose an 
opportune moment to examine factors which may begin to assist in equitable care as well as help 
delineate areas for reviewing policies and their impact on racial/ethnic disparities. 
 Quantitative and qualitative research (mixed methodology) within DMH services and state 
databases could assist in exploring factors which can be targeted for identifying and 
reducing disparities and can be addressed locally. Factors which might be examined are: 
the role of insurance type on prescribing patterns, use and retention of mental health 
services by racial-ethnic minority families of children with mental health disorders, 
qualitative examination of parental preferences, parent-provider agreement vs. differences 
in perceived need and treatment options, impact of standardized mental health screening 
and (diagnosis) on prescribing patterns, and whether the use of multimodal/combined 
treatments as recommended in current practice guidelines are practiced equitably. 
 The IOM definition distinguishes between health status, preferences and disparities. 
Competing arguments could be made to treat some factors either as measures of health 
status/preferences or as potential mediators of disparities. Geography is one such 
variable, but there are others, such as education, and nativity. Future research should 
focus on understanding the sources of disparities including identifying the various 
mediators which could be identified in empirical analysis. Understanding the important 
mediators of disparities can be very helpful in the development of policy. For example, 
disparities mediated through education or income might be very difficult to address in the 
short term, but disparities mediated through insurance coverage might be more amenable 
to changes in health policy.
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